1Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, RebeloM, Parkin DM, Forman D, Bray F. Cancer incidence and mortalityworldwide: sources, methods and major patterns in GLOBOCAN2012. Int J Cancer 2015; 136: E359-E386 [PMID: 25220842 DOI:10.1002/ijc.29210].
2Lombardi L, Morelli F, Cinieri S, Santini D, Silvestris N, Fazio N,Orlando L, Tonini G, Colucci G, Maiello E. Adjuvant colon cancerchemotherapy: where we are and where wel go. Cancer TreatRev 2010; 36 Suppl 3: S34-S41 [PMID: 21129608 DOI: 10.1016/S0305-7372(10)70018-9].
3Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmler C, Kahl C,Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J,Scholz M, Mler S, Link H, Niederle N, Rost A, Hfkes HG,Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, JungA, Stintzing S. FOLFIRI plus cetuximab versus FOLFIRI plusbevacizumab as first-line treatment for patients with metastaticcolorectal cancer (FIRE-3): a randomised, open-label, phase 3trial. Lancet Oncol 2014; 15: 1065-1075 [PMID: 25088940 DOI:10.1016/S1470-2045(14)70330-4].
4Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL,Hecht JR, Yu H, Oliner KS, Go WY. PEAK: a randomized, multicenterphase II study of panitumumab plus modified fluorouracil,leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plusmFOLFOX6 in patients with previously untreated, unresectable,wild-type KRAS exon 2 metastatic colorectal cancer. J ClinOncol 2014; 32: 2240-2247 [PMID: 24687833 DOI: 10.1200/JCO.2013.53.2473].
5Gustavsson B, Carlsson G, Machover D, Petrelli N, Roth A,Schmoll HJ, Tveit KM, Gibson F. A review of the evolution ofsystemic chemotherapy in the management of colorectal cancer. ClinColorectal Cancer 2015; 14: 1-10 [PMID: 25579803 DOI: 10.1016/j.clcc.2014.11.002].
6Lucas AS, Oeil BH, Goldberg RM. A decade of advances incytotoxic chemotherapy for metastatic colorectal cancer. ClinColorectal Cancer 2011; 10: 238-244 [PMID: 21820973 DOI:10.1016/j.clcc.2011.06.012].
7Heidelberger C, Chaudhuri NK, Danneberg P, Mooren D, GriesbachL, Duschinsky R, Schnitzer RJ, Pleven E, Scheiner J. Fluorinatedpyrimidines, a new class of tumour-inhibitory compounds. Nature1957; 179: 663-666 [PMID: 13418758 DOI: 10.1038/179663a0].
8Park JG, Collins JM, Gazdar AF, Allegra CJ, Steinberg SM, GreeneRF, Kramer BS. Enhancement of fluorinated pyrimidine-inducedcytotoxicity by leucovorin in human colorectal carcinoma cell lines.J Natl Cancer Inst 1988; 80: 1560-1564 [PMID: 2973527 DOI:10.1093/jnci/80.19.1560].
9Poon MA, O扖onnell MJ, Moertel CG, Wieand HS, Cullinan SA,Everson LK, Krook JE, Mailliard JA, Laurie JA, Tschetter LK.Biochemical modulation of fluorouracil: evidence of significantimprovement of survival and quality of life in patients with advancedcolorectal carcinoma. J Clin Oncol 1989; 7: 1407-1418 [PMID:2476530].
10Machover D, Schwarzenberg L, Goldschmidt E, Tourani JM,Michalski B, Hayat M, Dorval T, Misset JL, Jasmin C, Maral R,Math-G. Treatment of advanced colorectal and gastric adenocarcinomaswith 5-FU combined with high-dose folinic acid: a pilotstudy. Cancer Treat Rep 1982; 66: 1803-1807 [PMID: 6982099].
